Is Assembly Biosciences, Inc. (ASMB) a Buy, Sell, or Hold?
NASDAQ : ASMB
Assembly Biosciences, Inc.
$25.84 USD
-$0.89 (-3.33%)
- Volume
- 124.8K
- Average Volume
- 202.24K
- Market Capitalization
- $410.67M
- P/E Ratio
- -46.09
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $39.71
- Year Low
- $16.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.65
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jason A. Okazaki |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ASMB |
| CUSIP | 045396207 |
| CIK | 0001426800 |
| Web | https://www.assemblybio.com |
| Phone | 833 509 4583 |
| Currency | USD |
| Employees | 73 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.65 |
| Quick Ratio | 6.65 |
| Cash Ratio | 0.89 |
Sales & Book Value
| Annual Sales | $72.3M |
| Price / Sales | 5.98 |
| Cash Flow | -2.36 |
| Price / Cash Flow | -10.66 |
| Price / Book | 2.27 |
Price Target and Rating
| Average Stock Price Forecast | $45.00 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $45.00 |
| Forecast Upside/Downside | -42.58% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.55 |
| Trailing P/E Ratio | -46.09 |
| PEG Ratio | -0.22 |
| P/E Growth | -0.22 |
| Net Income | -$6.12M |
| Net Margin | -8.98% |
| Pretax Margin | -8.98% |
| Return on Equity | -4.21% |
| Return on Assets | -2.71% |
Financials Score
| AltmanZ Score | 3.13 |
| Piotroski Score | 3.00 |
| Working Capital | 197.62M |
| Total Assets | 235.51M |
| Ebit | -6.38M |
| Market Cap | 424.82M |
| Total Liabilities | 36.9M |
Poll Results
About Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it ... maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
2026-06-08 13:04:02
Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate into cholestatic liver diseases and expected clinical data readouts in 2027 and 2028.
2026-06-08 12:38:32
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
2026-06-05 15:03:52
Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event.
Assembly Biosciences Announces Upcoming Investor Conference Presentations
2026-05-28 16:05:00
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences:
2026-05-26 16:05:00
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, which includes the exercise in full by the underwriters of their option to purchase 566,040 additional shares of common stock. In addition, and in lieu of common stock, Assembly Bio sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 415,000 shares of common stock at an offering price per pre-funded warrant of $26.499, which represents the per share offering price of the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Assembly Bio from this offering were approximately $115.0 million before deducting underwriting discounts and commissions and other offering expenses payable by the company. Assembly Bio intends to use the net proceeds from the sale of the common stock and pre-funded warrants to fund clinical development of pipeline candidates and for general corporate purposes.
2026-05-22 07:05:00
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an offering price per share of common stock of $26.50, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 415,000 shares of common stock at an offering price per pre-funded warrant of $26.499, which represents the per share offering price of the common stock less the $0.001 exercise price per share for each pre-funded warrant. Gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $100 million. Assembly Bio has also granted the underwriters a 30-day option to purchase up to an additional 566,040 shares of common stock at the offering price, less underwriting discounts and commissions.
2026-05-22 07:00:00
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV –
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
2026-05-14 07:06:59
Assembly Biosciences NASDAQ: ASMB Chief Medical Officer Anuj Gaggar outlined the company's virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses.
Frequently Asked Questions
-
What is the current Assembly Biosciences, Inc. (ASMB) stock price?
-
Assembly Biosciences, Inc.(NASDAQ:ASMB) stock price is $25.84 in the last trading session. During the trading session, ASMB stock reached the peak price of $39.71 while $16.9 was the lowest point it dropped to. The percentage change in ASMB stock occurred in the recent session was --3.33% while the dollar amount for the price change in ASMB stock was -$0.89.
-
ASMB's industry and sector of operation?
-
The NASDAQ listed ASMB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ASMB?
-
Anuj Gaggar | Chief Medical Officer
Jason A. Okazaki | Chief Executive Officer, President & Director
Amy Figueroa | Investor Relations Consultant
William E. Delaney | Chief Scientific Officer
Katie Kitrinos | Senior Vice President of Preclinical Research & Development -
How many employees does ASMB have?
-
Number of ASMB employees currently stands at 73. ASMB operates from 331 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
Link for ASMB official website?
-
Official Website of ASMB is: https://www.assemblybio.com
-
How do I contact ASMB?
-
ASMB could be contacted at phone #833 509 4583 and can also be accessed through its website. ASMB operates from 331 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
How many shares of ASMB are traded daily?
-
The average number of ASMB shares traded daily for last 3 months was 202.24K.
-
What is the market cap of ASMB currently?
-
The market value of ASMB currently stands at $410.67M with its latest stock price at $25.84